Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019163 (
hepatitis B
)
38,309
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A fatal case of hepatic actinomycosis with portal vein thrombosis is reported. The diagnosis of actinomycosis was delayed because of its rarity in Taiwan. This 63-year-old man was admitted due to body weight loss and
poor appetite
. No fever was noted before admission. Liver biochemical test showed a decreased serum albumin level with elevated serum levels of globulin and alkaline phosphatase. He was not a
hepatitis B
carrier and his serum level of alfafetoprotein was within normal range. Image studies (abdominal sonography and computed tomography) showed a hepatic mass over the medial segment of the left lobe with involvement of right lobe of the liver. Main portal vein thrombosis was also seen. Because of profound cachexia, he died of aspiration pneumonia and disseminated intravascular coagulation on the 11th day after admission. An autopsy revealed hepatic actinomycosis. High index of suspicion for early diagnosis and treatment is emphasized.
...
PMID:Hepatic actinomycosis with portal vein thrombosis mimicking hepatocellular carcinoma: a case report. 839 99
Although an estimated 1 million persons in the United States are chronically infected with
hepatitis B
virus, the prevalence of
hepatitis B
has declined since the implementation of a national vaccination program.
Hepatitis B
virus is transmitted in blood and secretions. Acute infection may cause nonspecific symptoms, such as fatigue,
poor appetite
, nausea, vomiting, abdominal pain, low-grade fever, jaundice, and dark urine; and clinical signs, such as hepatomegaly and splenomegaly. Fewer than 5 percent of adults acutely infected with
hepatitis B
virus progress to chronic infection. The diagnosis of
hepatitis B
virus infection requires the evaluation of the patient's blood for
hepatitis B
surface antigen,
hepatitis B
surface antibody, and
hepatitis B
core antibody. The goals of treatment for chronic hepatitis B virus infection are to reduce inflammation of the liver and to prevent complications by suppressing viral replication. Treatment options include pegylated interferon alfa-2a administered subcutaneously or oral antiviral agents (nucleotide reverse transcriptase inhibitors). Persons with chronic hepatitis B virus infection should be monitored for disease activity with liver enzyme tests and
hepatitis B
virus DNA levels; considered for liver biopsy; and entered into a surveillance program for hepatocellular carcinoma.
...
PMID:Hepatitis B: diagnosis and treatment. 2038 72